BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29344636)

  • 1. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
    Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
    Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
    Sankhala K; Takimoto CH; Mita AC; Xiong H; Rodón J; Mehrvarz Sarshekeh A; Burns K; Iizuka K; Kopetz S
    Invest New Drugs; 2019 Feb; 37(1):76-86. PubMed ID: 29667134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polyethylene glycol-conjugate of deoxycytidine analog, DFP-14927, produces potential antitumor effects on pancreatic tumor-xenograft murine models via inducing G2/M arrest.
    Ando H; Eshima K; Ishida T
    Eur J Pharmacol; 2023 Jul; 950():175758. PubMed ID: 37121563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
    Azuma A; Huang P; Matsuda A; Plunkett W
    Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
    Liu XJ; Nowak B; Wang YQ; Plunkett W
    Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
    Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
    Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity.
    Miura S; Yoshimura Y; Endo M; Satoh H; Machida H; Sasaki T
    Cancer Lett; 1999 Oct; 144(2):177-82. PubMed ID: 10529018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
    Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
    J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
    Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
    Drug Des Devel Ther; 2016; 10():1299-306. PubMed ID: 27099475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
    Toner LE; Vrhovac R; Smith EA; Gardner J; Heaney M; Gonen M; Teruya-Feldstein J; Sirotnak F; O'Connor OA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):924-32. PubMed ID: 16467107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
    Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
    Tanaka M; Matsuda A; Terao T; Sasaki T
    Cancer Lett; 1992 May; 64(1):67-74. PubMed ID: 1596880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.
    Mehrvarz Sarshekeh A; Xiong HQ; Iizuka K; Hochster HS; Kopetz S
    Invest New Drugs; 2018 Oct; 36(5):895-902. PubMed ID: 29948357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
    Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.